Skip to content

Resting-State Functional Magnetic Resonance Imaging–Guided Personalization of Transcranial Magnetic Stimulation Treatment for Depression

Resting-State Functional Magnetic Resonance Imaging–Guided Personalization of Transcranial Magnetic Stimulation Treatment for Depression

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400092540
Enrollment
Unknown
Registered
2024-11-19
Start date
2024-11-20
Completion date
Unknown
Last updated
2024-12-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

depression

Interventions

Experimental group1:Functional connectivity localization group
Experimental group2:Classical coordinate localization group
Healthy control group:None

Sponsors

The Affiliated Hospital of Hangzhou Normal University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: (1) Patients diagnosed with depression who meet the DSM-5 criteria for depression diagnosis; (2) HAMD>17 points (Melzer et al., 2012); The Chinese version of the Mood Disorder Questionnaire (MDQ) scores less than 7 points; (3) Using the Brief International Neuropsychiatric Interview 7.0.0 (M.I.N.I. 7.0.0) to confirm that the subject is currently experiencing a depressive episode; (4) Gender is not limited, age range is 18-65 years old; (5) Subjects who can understand and are willing to strictly follow the clinical trial protocol to complete this trial and sign the informed consent form.

Exclusion criteria

Exclusion criteria: (1) Individuals with contraindications to magnetic resonance imaging and TMS. (2) Serious heart, liver, and kidney diseases, no history of thyroid, tumor, hematological disorders, rheumatism, malnutrition, or neurological disorders. (3) Schizophrenia, bipolar disorder, history of tobacco, alcohol, and other psychoactive substance abuse. (4) The patient is a pregnant or lactating woman or a planned pregnancy. (5) Not taking immune modulators and hormone preparations for at least six months, and not taking antipyretic and analgesic drugs for two weeks. (6) Patients who have received ECT or TMS treatment within two months. (7) Researchers believe that it is not suitable for inclusion.

Design outcomes

Primary

MeasureTime frame
Hamilton Depression Scale;

Secondary

MeasureTime frame
Hamilton Anxiety Scale;Self-rating depression scale;Anxiety self-rating scale;Insomnia Severity Index Scale;Baker Suicidal Ideation Scale;Visual analogue scale;Mood Disorder Questionnaire;Snaith-Hamilton Pleasure Scale;Digit-symbol substitution test;digital span test;

Countries

China

Contacts

Public ContactZhao Na

Hangzhou Normal University

nazhaon@163.com+86 153 8231 0496

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026